A Phase II Study of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Share
Print

Full Title

NF110: Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (UAB)

Purpose

The purpose of this study is to assess the safety and effectiveness of the drug crizotinib in children and adults with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas. Crizotinib blocks an enzyme involved in tumor growth. It is used to treat certain types of lung cancer in adults and a form of lymphoma in children, adolescents, and young adults. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have NF2 and a progressive vestibular schwannoma that continues to grow.
  • At least 4 weeks must pass since the completion of prior therapies and receipt of crizotinib.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 6 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Matthias Karajannis at 212-639-3369.

Protocol

21-028

Phase

II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators